Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.42 |
| ▸ | FAAH | O00519 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30899631 | 1.00 | MEN1 (0.45) | MEN1KMT2ANPSR1USP2HPGD | |
| SCHEMBL30366230 | 0.88 | MEN1 (0.46) | MEN1KMT2ANPSR1USP2HPGD | |
| SCHEMBL30366202 | 0.88 | MEN1 (0.46) | MEN1KMT2ANPSR1USP2HPGD | |
| SCHEMBL30899632 | 0.87 | PDE4B (0.43) | MEN1KMT2ANPSR1USP2HPGD | |
| SCHEMBL30366333 | 0.87 | PDE4B (0.43) | MEN1KMT2ANPSR1USP2HPGD | |
| SCHEMBL30294196 | 0.86 | MEN1 (0.52) | MEN1KMT2ANPSR1USP2HPGD | |
| SCHEMBL18741911 | 0.86 | MEN1 (0.52) | MEN1KMT2ANPSR1USP2HPGD | |
| SCHEMBL23062504 | 0.86 | MEN1 (0.46) | MEN1KMT2ANPSR1USP2HPGD | |
| SCHEMBL21382064 | 0.84 | USP30 (0.42) | USP30GPR119 | |
| SCHEMBL30567979 | 0.84 | USP30 (0.42) | USP30GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360126-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2024-10-31 | — | — | US | disclosed |
| EP-4405051-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2024-07-31 | — | — | EP | disclosed |
| WO-2023046806-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2023-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360126-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | SSB, TPMT, KCNB2 | MEN1 256/4885KMT2A 905/4885NPSR1 1964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.